Forte, N;
Chudasama, V;
Baker, JR;
(2018)
Homogeneous antibody-drug conjugates via site-selective disulfide bridging.
Drug Discovery Today: Technologies
, 30
pp. 11-20.
10.1016/j.ddtec.2018.09.004.
Preview |
Text
Review_Final_to upload.pdf - Accepted Version Download (750kB) | Preview |
Abstract
Antibody-drug conjugates (ADCs) constructed using site-selective labelling methodologies are likely to dominate the next generation of these targeted therapeutics. To this end, disulfide bridging has emerged as a leading strategy as it allows the production of highly homogeneous ADCs without the need for antibody engineering. It consists of targeting reduced interchain disulfide bonds with reagents which reconnect the resultant pairs of cysteine residues, whilst simultaneously attaching drugs. The 3 main reagent classes which have been exemplified for the construction of ADCs by disulfide bridging will be discussed in this review; bissulfones, next generation maleimides and pyridazinediones, along with others in development.
| Type: | Article |
|---|---|
| Title: | Homogeneous antibody-drug conjugates via site-selective disulfide bridging |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ddtec.2018.09.004 |
| Publisher version: | https://doi.org/10.1016/j.ddtec.2018.09.004 |
| Language: | English |
| Additional information: | This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences > Dept of Chemistry |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10060847 |
Archive Staff Only
 |
View Item |
